Exicure, Inc.

Industry

  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Technologies
    • Antisense, Oligonucleotides

Other Names/Subsidiaries

  • AuraSense Therapeutics
  • AuraSense Therapeutics
  • Exicure OpCo
  • Max-1 Acquisition Corporation
See more in Biomedtracker

Latest on Exicure, Inc.

Scrip

Deal Watch: Novo Nordisk, IMMvention To Partner On Sickle Cell Disease

 
• By Joseph Haas, Dexter Jie Yan, Xu Hu, and Vibha Ravi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novo Nordisk, IMMvention Collaboration

Scrip

Deal Watch: Bristol To Link Up With VantAI On Molecular Glue Therapies

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Bristol, VantAI Pair Technologies In Pr

Scrip

Finance Watch: Ferring Shutters San Diego R&D Site As Even Money-Making Firms Cut Costs

 
• By Mandy Jackson

With investors closely watching how biopharmaceutical companies are spending the cash they have on hand so that they do not run out of money in a tough fundraising environment, even firms with revenue

Scrip

Finance Watch: SPAC Deals Emerge As IPO Market Goes Quiet Again

 
• By Mandy Jackson

The biopharmaceutical industry cheered Third Harmonic Bio ’s sizeable initial public offering in mid-September but the IPO market in the US has gone quiet since then as broader stock indices – includ